Quick Answer
Arcturus Therapeutics Holdings Inc. reported Total Assets of $271.15 million for the year ending 2025.
- Arcturus Therapeutics Holdings Inc. showed a decrease of -21.2% in Total Assets from 2024 to 2025.
- This data is from Arcturus Therapeutics Holdings Inc.'s annual report (Form 10-K), filed with the SEC on March 3, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $70.94 million | Q3 2019: $87.22 million | Q1 2020: $72.10 million | Q2 2020: $149.94 million | Q3 2020: $322.52 million | Q1 2021: $481.47 million | Q2 2021: $448.81 million | Q3 2021: $434.54 million | Q1 2022: $341.99 million | Q2 2022: $337.01 million | Q3 2022: $293.63 million | Q1 2023: $470.86 million | Q2 2023: $430.65 million | Q3 2023: $457.65 million | Q1 2024: $418.85 million | Q2 2024: $388.61 million | Q3 2024: $370.65 million | Q1 2025: $331.79 million | Q2 2025: $309.27 million | Q3 2025: $282.34 million.
- Over the full 8 years of available data (2018 to 2025), Arcturus Therapeutics Holdings Inc.'s Total Assets has grown by 513.5%.
- Historical annual values: Fiscal year 2025: $271.15 million | Fiscal year 2024: $344.07 million | Fiscal year 2023: $429.40 million | Fiscal year 2022: $450.39 million | Fiscal year 2021: $392.81 million | Fiscal year 2020: $476.46 million | Fiscal year 2019: $82.14 million | Fiscal year 2018: $44.20 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: